Intellia Therapeutics

CAMBRIDGE, MA · Founded 2014 · Biotech · Public

CRISPR-based genome editing therapeutics

Claim this profile

Follows are private to you and power your alerts

Updated · intelliatx.com

Sector
Biotech
Headquarters
CAMBRIDGE, MA
Founded
2014
Latest Form D
$70M, Sep 2015
Total capital
$70M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$70M
1 Form D · last Sep 2015
134 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
9
31 pending · first 2024
Rank in peer group#89 of 1449

Capital timeline

2015FEDERAL ↑EQUITY ↓Cumulative $70M1st Form D$70M
2015FEDERAL ↑EQUITY ↓Cumulative $70M1st Form D$70M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$70M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#89 · top 6%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Carl GordonDirectorNamed in SEC Form D filings
  • Jean-Francois FormelaDirectorNamed in SEC Form D filings
  • John LeonardExecutive Officer, DirectorNamed in SEC Form D filings
  • Jose RiveraExecutive OfficerNamed in SEC Form D filings
  • Nessan BerminghamExecutive Officer, DirectorNamed in SEC Form D filings
  • Rachel HaurwitzDirectorNamed in SEC Form D filings

What it has protected

USPTO · 9 granted of 40
  • GrantedModified Guide RNAsUSPTOUS 12,735,698
  • PendingCompositions And Methods For The Treatment Of HemoglobinopathiesUSPTOApplication 19364537
  • PendingCompositions and Methods for TTR Gene Editing and Treating ATTR Amyloidosis Comprising a Corticosteroid or Use ThereofUSPTOApplication 19295369
Show all 40 patent records
  • Modified Guide RNAsSep 15, 2026 · US 12,735,698Granted
  • Compositions And Methods For The Treatment Of HemoglobinopathiesSep 10, 2026 · Application 19364537Pending
  • Compositions and Methods for TTR Gene Editing and Treating ATTR Amyloidosis Comprising a Corticosteroid or Use ThereofAug 27, 2026 · Application 19295369Pending
  • Ionizable Amine LipidsAug 6, 2026 · Application 19354595Pending
  • Compositions and Methods for ImmunotherapyJul 23, 2026 · Application 19357943Pending
  • Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding AgentJul 21, 2026 · US 12,686,876Granted
  • Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding AgentJul 16, 2026 · Application 19630254Pending
  • Compositions and Methods for Kallikrein (KLKB1) Gene EditingJul 7, 2026 · US 12,674,151Granted
  • Compositions and Methods for ImmunotherapyMay 19, 2026 · US 12,630,820Granted
  • Polynucleotides, Compositions, and Methods for Genome EditingMay 14, 2026 · Application 19439064Pending
  • Compositions And Methods For Treating ALPHA-1 Antitrypsin DeficiencyMay 7, 2026 · Application 19337426Pending
  • Compositions and Methods for Treating Alpha-1 Antitrypsin DeficiencyMay 7, 2026 · Application 19353412Pending
  • Compositions and Methods for Kallikrein (KLKB1) Gene EditingMay 7, 2026 · Application 19327529Pending
  • Compositions And Methods For The Treatment Of HemoglobinopathiesFeb 24, 2026 · US 12,559,748Granted
  • Compositions and Methods for Hydroxyacid Oxidase 1 (HAO1) Gene Editing for Treating Primary Hyperoxaluria Type 1 (PH1)Feb 12, 2026 · Application 19246289Pending
  • Compositions and Methods for Lactate Dehydrogenase (LDHA) Gene EditingFeb 5, 2026 · Application 19210426Pending
  • Modified Guide RNAsJan 15, 2026 · Application 19256778Pending
  • Compositions And Methods For Treating ALPHA-1 Antitrypsin DeficiencyJan 8, 2026 · Application 18700487Pending
  • Systems and Methods for Genomic EditingDec 11, 2025 · Application 19241998Pending
  • Compositions and Methods for Kallikrein (KLKB1) Gene EditingNov 25, 2025 · US 12,480,109Granted
  • Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA)Nov 13, 2025 · Application 19276658Pending
  • Compositions and Methods for Treating Alpha-1 Antitrypsin DeficiencyNov 4, 2025 · US 12,460,205Granted
  • Compositions and Methods for Proprotein Convertase Subtilisin Kexin 9 (PCSK9) EditingOct 9, 2025 · Application 19242255Pending
  • CD38 Compositions And Methods For ImmunotherapyOct 2, 2025 · Application 18706899Pending
  • Methods and Compositions for Genetically Modifying a CellSep 4, 2025 · Application 18980643Pending
  • Compositions and Methods for Genomic EditingSep 4, 2025 · Application 18980502Pending
  • Methods For In Vivo Editing Of A Liver GeneAug 28, 2025 · Application 18572155Pending
  • Chimeric Antigen Receptor Compositions And UsesAug 28, 2025 · Application 18857966Pending
  • Compositions and Methods for Reducing MHC Class I in a CellAug 21, 2025 · Application 18980462Pending
  • Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA)Aug 19, 2025 · US 12,391,722Granted
  • Compositions and Methods for TTR Gene Editing and Treating ATTR AmyloidosisJun 26, 2025 · Application 18940080Pending
  • Compositions And Methods For ImmunooncologyApr 3, 2025 · Application 18486393Pending
  • Lipid Nanoparticle CompositionsMar 20, 2025 · Application 18287239Pending
  • Modified Amine LipidsMar 6, 2025 · Application 18796047Pending
  • Modified Guide RNAsFeb 20, 2025 · Application 18941127Pending
  • Crispr-mediated Transgene Insertion In Neonatal CellsJan 30, 2025 · Application 18835246Pending
  • Compositions and Methods for Treatment of Diseases Associated with Trinucleotide Repeats in Transcription Factor FourJan 23, 2025 · Application 18415032Pending
  • Modified Guide RNAsDec 24, 2024 · US 12,173,284Granted
  • Compositions And Methods For ImmunooncologyDec 19, 2024 · Application 18534209Pending
  • Methods Of Genotyping Adeno-associated Virus Inverted Terminal Repeat Sequences In Plasmids Using Fixed Flanking Sequence Marker-based Extraction And ClusteringDec 19, 2024 · Application 18742805Pending
  • Ethyreal BioSimilar federal contract value in Biotech · null in contracts
  • Dyne TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Kailera TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Judo BioSimilar federal contract value in Biotech · null in contracts
  • Kinaset TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Korro BioSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .